EcoDrugPlus

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSEEUG00000006019
Gene Symbol: PSMD2
1 External references
224 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSEEUG00000010473
Gene Symbol: PSMD4
1 External references
293 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSEEUG00000003903
Gene Symbol: PSMC1
1 External references
316 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSEEUG00000004103
Gene Symbol: PSMC2
1 External references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSEEUG00000001016
Gene Symbol: PSMC3
1 External references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSEEUG00000000782
Gene Symbol: PSMC4
1 External references
199 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSEEUG00000002735
Gene Symbol: PSMC6
1 External references
237 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSEEUG00000002726
Gene Symbol: PSMD1
1 External references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSEEUG00000003048
Gene Symbol: PSMD11
1 External references
283 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSEEUG00000002939
Gene Symbol: PSMD12
1 External references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 3

Ensembl ID : ENSEEUG00000013752
Gene Symbol: PSMD3
1 External references
94 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSEEUG00000007240
Gene Symbol: PSMD6
1 External references
213 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).